Phreesia Faces Class Action Lawsuit Reminder for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 58 minutes ago
0mins
Source: Globenewswire
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Phreesia for violations of the Securities Exchange Act, concerning securities purchased between May 8, 2025, and March 30, 2026, with a deadline for contact set for July 13, 2026.
- False Statement Allegations: The complaint alleges that Phreesia made false and misleading statements regarding its long-term growth outlook, claiming confidence in growth projections despite uncertainties that could jeopardize revenue targets, leading to investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, emphasizing its specialization in securities class action lawsuits and shareholder rights litigation, aiming to assist investors in recovering their losses.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, highlighting the importance of participating in the lawsuit to avoid being an absent class member.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.780
Low
24.00
Averages
29.09
High
35.00
Current: 8.780
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phreesia Faces Class Action Lawsuit Reminder for Investors
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Phreesia for violations of the Securities Exchange Act, concerning securities purchased between May 8, 2025, and March 30, 2026, with a deadline for contact set for July 13, 2026.
- False Statement Allegations: The complaint alleges that Phreesia made false and misleading statements regarding its long-term growth outlook, claiming confidence in growth projections despite uncertainties that could jeopardize revenue targets, leading to investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, emphasizing its specialization in securities class action lawsuits and shareholder rights litigation, aiming to assist investors in recovering their losses.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, highlighting the importance of participating in the lawsuit to avoid being an absent class member.
See More
Phreesia Inc. Under Investigation for Securities Law Violations
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal 2027, attributing this to macroeconomic factors including 'worsening visibility,' which could adversely affect the company's financial stability and investor confidence.
- Stock Price Plunge: Following the announcement of lowered revenue expectations, Phreesia's stock price fell by $3.03, or 26.6%, closing at $8.38 per share on March 31, 2026, resulting in substantial losses for investors.
- Legal Investigation Launched: The Law Offices of Howard G. Smith have initiated an investigation into Phreesia to assess potential violations of federal securities laws, which could expose the company to legal liabilities and impact its future operations.
- Investor Rights Advocacy: The law firm is urging all investors who suffered losses in Phreesia to contact them to explore potential claims, highlighting the importance of protecting investor rights and the necessity for legal support in such situations.
See More
Phreesia Securities Fraud Class Action Reminder
- Lawsuit Background: Kirby McInerney LLP reminds investors who purchased Phreesia securities between May 8, 2025, and March 30, 2026, of a class action lawsuit alleging the company made materially false statements, with a deadline of July 13, 2026, to apply for lead plaintiff status to represent the class.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in its revenue growth projections for fiscal year 2027, attributing this to macroeconomic factors and weakened pharmaceutical marketing commitments, which poses risks to the company's revenue streams and investor confidence.
- Stock Price Volatility: Following the announcement on March 30, Phreesia's stock price plummeted from $11.41 to $8.38, a decline of approximately 27%, indicating market concerns over the company's future revenue outlook and potential for increased investor losses.
- Market Impact: CEO Chaim Indig previously stated that the acquisition of AccessOne would expand the addressable market by roughly $6 billion, yet the actual performance fell short, highlighting a significant gap between company commitments and actual results, which could undermine future financing capabilities and investor trust.
See More
Phreesia Shareholders File Class Action Amid Marketing Commitment Concerns
- Class Action Filed: Phreesia, Inc. (NYSE:PHR) faces a class action lawsuit from shareholders who purchased securities between May 8, 2025, and March 30, 2026, due to alleged failure to disclose deteriorating pharmaceutical marketing commitments, indicating a significant disconnect between internal knowledge and public communication that could undermine investor confidence.
- Significant Stock Decline: Following the March 30, 2026 disclosure that pharmaceutical manufacturers were committing far less than anticipated, Phreesia's stock price plummeted by $3.03, a 27% drop, reflecting heightened market concerns regarding the company's future profitability and stability.
- Internal vs. External Information Discrepancy: The lawsuit alleges that Phreesia's management was aware of weakening pharmaceutical demand yet publicly reassured investors with optimistic statements, leading shareholders to purchase stock at artificially inflated prices, resulting in substantial financial losses when the truth emerged.
- Legal Implications for Investor Rights: The lawsuit raises critical questions about the timing of risk disclosures, potentially causing shareholders to make uninformed investment decisions, and investors are urged to submit claims by July 13, 2026, to safeguard their rights.
See More
Class Action Lawsuit Announced for Phreesia, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Phreesia, Inc. (NYSE:PHR) common stock purchasers from May 8, 2025, to March 30, 2026, indicating potential investor losses due to the company's misleading statements.
- Compensation Structure: Investors joining the lawsuit will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers and encouraging more affected parties to participate.
- Lawsuit Context: The lawsuit alleges that Phreesia concealed adverse facts, such as weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to investor damages when the truth emerged, which could significantly undermine the company's market credibility.
- Legal Counsel Recommendation: Rosen Law Firm advises investors to select qualified counsel with a proven track record in securities class actions, emphasizing their expertise and historical success to ensure effective protection of investor rights.
See More
Analyst Downgrades Phreesia Rating and Price Target
- Rating Downgrade Impact: Wells Fargo analyst Stan Berenshteyn downgraded Phreesia's rating from overweight to equal weight, resulting in a 3.5% drop in the stock during a trading session where the S&P 500 rose over 1%, indicating market concerns about its future performance.
- Significant Price Target Cut: The analyst slashed Phreesia's price target from $15 to $9, nearly halving it, which reflects a pessimistic outlook on the company's future revenue growth amid increasing competition in the healthcare tech sector.
- Revenue Estimates Reduced: Due to heightened competition, the analyst lowered expectations for Phreesia's crucial subscription revenue, noting that patient intake software is more replaceable than workflow software, thereby exposing the company to greater market pressures.
- Client Base Risk: The analyst highlighted that Phreesia's strength lies in private practitioners, a segment increasingly targeted by smaller developers, which further exacerbates the company's competitive risks and could impact its market share.
See More
Phreesia Faces Class Action Lawsuit Reminder for Investors
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Phreesia for violations of the Securities Exchange Act, concerning securities purchased between May 8, 2025, and March 30, 2026, with a deadline for contact set for July 13, 2026.
- False Statement Allegations: The complaint alleges that Phreesia made false and misleading statements regarding its long-term growth outlook, claiming confidence in growth projections despite uncertainties that could jeopardize revenue targets, leading to investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected investors, emphasizing its specialization in securities class action lawsuits and shareholder rights litigation, aiming to assist investors in recovering their losses.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, highlighting the importance of participating in the lawsuit to avoid being an absent class member.
See More
Phreesia Inc. Under Investigation for Securities Law Violations
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal 2027, attributing this to macroeconomic factors including 'worsening visibility,' which could adversely affect the company's financial stability and investor confidence.
- Stock Price Plunge: Following the announcement of lowered revenue expectations, Phreesia's stock price fell by $3.03, or 26.6%, closing at $8.38 per share on March 31, 2026, resulting in substantial losses for investors.
- Legal Investigation Launched: The Law Offices of Howard G. Smith have initiated an investigation into Phreesia to assess potential violations of federal securities laws, which could expose the company to legal liabilities and impact its future operations.
- Investor Rights Advocacy: The law firm is urging all investors who suffered losses in Phreesia to contact them to explore potential claims, highlighting the importance of protecting investor rights and the necessity for legal support in such situations.
See More
Phreesia Securities Fraud Class Action Reminder
- Lawsuit Background: Kirby McInerney LLP reminds investors who purchased Phreesia securities between May 8, 2025, and March 30, 2026, of a class action lawsuit alleging the company made materially false statements, with a deadline of July 13, 2026, to apply for lead plaintiff status to represent the class.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in its revenue growth projections for fiscal year 2027, attributing this to macroeconomic factors and weakened pharmaceutical marketing commitments, which poses risks to the company's revenue streams and investor confidence.
- Stock Price Volatility: Following the announcement on March 30, Phreesia's stock price plummeted from $11.41 to $8.38, a decline of approximately 27%, indicating market concerns over the company's future revenue outlook and potential for increased investor losses.
- Market Impact: CEO Chaim Indig previously stated that the acquisition of AccessOne would expand the addressable market by roughly $6 billion, yet the actual performance fell short, highlighting a significant gap between company commitments and actual results, which could undermine future financing capabilities and investor trust.
See More
Phreesia Shareholders File Class Action Amid Marketing Commitment Concerns
- Class Action Filed: Phreesia, Inc. (NYSE:PHR) faces a class action lawsuit from shareholders who purchased securities between May 8, 2025, and March 30, 2026, due to alleged failure to disclose deteriorating pharmaceutical marketing commitments, indicating a significant disconnect between internal knowledge and public communication that could undermine investor confidence.
- Significant Stock Decline: Following the March 30, 2026 disclosure that pharmaceutical manufacturers were committing far less than anticipated, Phreesia's stock price plummeted by $3.03, a 27% drop, reflecting heightened market concerns regarding the company's future profitability and stability.
- Internal vs. External Information Discrepancy: The lawsuit alleges that Phreesia's management was aware of weakening pharmaceutical demand yet publicly reassured investors with optimistic statements, leading shareholders to purchase stock at artificially inflated prices, resulting in substantial financial losses when the truth emerged.
- Legal Implications for Investor Rights: The lawsuit raises critical questions about the timing of risk disclosures, potentially causing shareholders to make uninformed investment decisions, and investors are urged to submit claims by July 13, 2026, to safeguard their rights.
See More
Class Action Lawsuit Announced for Phreesia, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Phreesia, Inc. (NYSE:PHR) common stock purchasers from May 8, 2025, to March 30, 2026, indicating potential investor losses due to the company's misleading statements.
- Compensation Structure: Investors joining the lawsuit will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers and encouraging more affected parties to participate.
- Lawsuit Context: The lawsuit alleges that Phreesia concealed adverse facts, such as weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to investor damages when the truth emerged, which could significantly undermine the company's market credibility.
- Legal Counsel Recommendation: Rosen Law Firm advises investors to select qualified counsel with a proven track record in securities class actions, emphasizing their expertise and historical success to ensure effective protection of investor rights.
See More
Analyst Downgrades Phreesia Rating and Price Target
- Rating Downgrade Impact: Wells Fargo analyst Stan Berenshteyn downgraded Phreesia's rating from overweight to equal weight, resulting in a 3.5% drop in the stock during a trading session where the S&P 500 rose over 1%, indicating market concerns about its future performance.
- Significant Price Target Cut: The analyst slashed Phreesia's price target from $15 to $9, nearly halving it, which reflects a pessimistic outlook on the company's future revenue growth amid increasing competition in the healthcare tech sector.
- Revenue Estimates Reduced: Due to heightened competition, the analyst lowered expectations for Phreesia's crucial subscription revenue, noting that patient intake software is more replaceable than workflow software, thereby exposing the company to greater market pressures.
- Client Base Risk: The analyst highlighted that Phreesia's strength lies in private practitioners, a segment increasingly targeted by smaller developers, which further exacerbates the company's competitive risks and could impact its market share.
See More
